Study finds radiation best treatment for a rare skin cancer

Radiation treatment can help reduce the recurrence of Merkel cell carcinoma, a rare and aggressive skin cancer, while chemotherapy does not appear to have any impact on recurrence or survival, according to a Kaiser Permanente study published online in the current issue of JAMA Dermatology.

The study presents one of the largest single-institution datasets on Merkel cell carcinoma, which occurs in about 1,500 people in the United States annually. Most such cancers occur on the sun-exposed skin of white males and are first diagnosed at age 75, on average. Using the Kaiser Permanente Northern California Cancer Registry, the researchers found that out of 218 cases of Kaiser Permanente patients who had Merkel cell carcinoma, those who had had a 70 percent lower risk of while chemotherapy did not appear to have any impact on recurrence or survival.

"We used our database to show what characteristics impact recurrence and survival in this very rare cancer," said the study's lead author Maryam M. Asgari, MD, MPH, of the Kaiser Permanente Division of Research. "The electronic records allowed us to identify patients with Merkel cell carcinoma, see how they were diagnosed and treated, and then follow them over time to see how their care affected their outcomes."

Using an electronic health record system, Kaiser Permanente HealthConnect, allowed the researchers to evaluate the relationships between and survival with demographic information (age, sex, race, immunosuppression) and tumor characteristics (extent, size and location), as well as work-ups (pathologic lymph node evaluation, imaging) and treatments (surgery, radiation and chemotherapy).

The study results also showed that immunosuppression and more advanced tumors were associated with worse survival rates related to Merkel cell carcinoma, and that pathological evaluation of the patient's lymph nodes also had a significant impact on outcomes.

Asgari noted that the success of different work-up and treatment protocols has been difficult to compare for rare cancers. "This research should help dermatologists and oncologists in caring for their patients with Merkel cell carcinomas," she said.

add to favorites email to friend print save as pdf

Related Stories

Less invasive technique possible in vulvar cancer treatment

Mar 26, 2014

A team of researchers from Women & Infants Hospital of Rhode Island commanded a national stage to present the results of a study evaluating the use of sentinel lymph node dissection in women with vulvar malignancies, and ...

Recommended for you

The fine line between breast cancer and normal tissues

5 hours ago

Up to 40 percent of patients undergoing breast cancer surgery require additional operations because surgeons may fail to remove all the cancerous tissue in the initial operation. However, researchers at Brigham ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

6 hours ago

(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according ...

Good bowel cleansing is key for high-quality colonoscopy

8 hours ago

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task ...

New rules for anticancer vaccines

10 hours ago

Scientists have found a way to find the proverbial needle in the cancer antigen haystack, according to a report published in The Journal of Experimental Medicine.

User comments